Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 5/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12461274 | 0.95 | BRAF (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL16510709 | 0.86 | ALDH1A1 (0.65) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461320 | 0.85 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461264 | 0.85 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461239 | 0.85 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461260 | 0.82 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461214 | 0.82 | ALDH1A1 (0.57) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461261 | 0.82 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12461340 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL12462133 | 0.80 | ALDH1A1 (0.64) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 2358/4885ALDH1A1 2793/4885SMN1; SMN2 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.